Patient Decision Aid for Antidepressant Use in Pregnancy

Overview

The purpose of this pilot study is to examine the feasibility of conducting a multi-site randomized controlled trial whose aim will be to evaluate the effectiveness of a Patient Decision Aid (PDA) for antidepressant use in pregnancy.

Full Title of Study: “Patient Decision Aid (PDA) for Antidepressant Use In Pregnancy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Health Services Research
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: April 2017

Detailed Description

Depression in pregnancy is common, affecting up to 10% of women and represents serious risk to mother and infant. Unfortunately, antidepressant medication, a first-line treatment for depression in pregnancy, also comes with risks, making this a complex decision. Clinical care appears to be insufficient for ensuring that women make decisions that are consistent with their own values and with which they feel satisfied. Patient decision support tools can address such barriers. We have created a patient decision aid (PDA) that has the potential to improve the decision-making process for women regarding antidepressant use in pregnancy in conjunction with clinical care. The overall objective of this project is to inform the development of a larger, international RCT to assess the efficacy of our PDA for antidepressant use in pregnancy. To achieve this objective, we will assess the feasibility of our clinical trial protocol to evaluate the PDA and determine the preliminary effect size for a larger multi-site efficacy study. The primary outcome for this pilot study is the feasibility of conducting a large randomized controlled trial to evaluate the efficacy of the PDA. This includes feasibility (how well the trial protocol can be implemented), acceptability (usability and tolerability of the intervention) and adherence (the degree to which the trial protocol is followed). We hypothesize that our protocol will be feasible, that the PDA will have a high degree of acceptability, and that adherence to the protocol will be high.

Interventions

  • Behavioral: Electronic Patient Decision Aid
    • The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections: Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure; (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and A summary section that outlines the information reviewed and which benefits and risks they deemed most important.
  • Behavioral: Standard Resource Sheet
    • Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA). Women who are assigned the control condition AND who are not receiving care from Women’s College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization.

Arms, Groups and Cohorts

  • Placebo Comparator: Standard Resource Sheet
    • Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
  • Active Comparator: Electronic Patient Decision Aid
    • The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections: Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure; (a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and A summary section that outlines the information reviewed and which benefits and risks they deemed most important. At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator.

Clinical Trial Outcome Measures

Primary Measures

  • Recruitment Rate
    • Time Frame: Up to one year from when the study starts enrolling participants
    • Feasibility: Number of participants recruited into the study over Number of eligible patients

Secondary Measures

  • Decisional Conflict Scale
    • Time Frame: Baseline (pre-randomization)
  • Knowledge about antidepressant treatment in pregnancy
    • Time Frame: Baseline (pre-randomization)
  • Edinburgh Postnatal Depression Scale
    • Time Frame: Baseline (pre-randomization)
  • Spielburg State-Trait Anxiety Inventory
    • Time Frame: Baseline (pre-randomization)
  • Edinburgh Postnatal Depression Scale
    • Time Frame: 4 Weeks post-randomization
  • Edinburgh Postnatal Depression Scale
    • Time Frame: 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), only for participants who are seeing specialty psychiatric services
  • Spielburg State-Trait Anxiety Inventory
    • Time Frame: 4 Weeks post-randomization
  • Spielburg State-Trait Anxiety Inventory
    • Time Frame: 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), only for participants who are seeing specialty psychiatric services
  • Decisional Conflict Scale
    • Time Frame: 4 Weeks post-randomization
  • Knowledge about antidepressant treatment in pregnancy
    • Time Frame: 4 Weeks post-randomization
  • PDA Acceptability Questionnaire
    • Time Frame: 4 Weeks post-randomization
  • Provider Perspective Survey
    • Time Frame: After all other participant data has been collected
  • Treatment Decision(s)
    • Time Frame: Baseline (pre-randomization)
  • Treatment Decision(s)
    • Time Frame: 4 Weeks post-randomization
  • Treatment Decision(s)
    • Time Frame: 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), only for participants who are seeing specialty psychiatric services
  • Time between recruitment to first log-in to the study website
    • Time Frame: 4 weeks post-randomization
  • Self-reported satisfaction with the PDA by the participants
    • Time Frame: 4 Weeks post-randomization
  • Provider’s perspective on the utility of the PDA in clinical practice
    • Time Frame: After all participant data has been collected
  • Study Website Usage
    • Time Frame: 4 Weeks post-randomization
    • Composite measure comprised of: (1) number of participants who complete the PDA, (2) length of time required to complete the PDA, (3) number of log ins, (4) number of times the PDA is completed per participant, (5) total number of webpages viewed).
  • Number of participants who follow-up with their physician during the intended timeline
    • Time Frame: 4 weeks post-randomization, only for participants who are seeing specialty psychiatric services
  • The rate of follow-up data collection
    • Time Frame: 4 Weeks post-randomization
  • The rate of follow-up data collection
    • Time Frame: 12 weeks postpartum (for participants who enrolled while pregnant) OR 6 months post-randomization (for women who enrolled while planning a pregnancy), OR at 4 weeks post-randomization for women who are NOT seeing specialty perinatal psychiatry services

Participating in This Clinical Trial

Inclusion Criteria

1. Are females aged >18 years old, and 2. Are either planning a pregnancy OR are <30 weeks gestation at enrollment, and 3. Have been offered to start or continue SSRI or SNRI anti-depressant medication as a treatment option for depression by their clinical provider at one of the study sites, and 4. Have moderate-to-high decisional conflict (score of >25 on the Decisional Conflict Scale) Exclusion criteria:

1. Have had alcohol or substance abuse or dependence in the previous 12 months, or 2. Have active suicidal ideation or psychosis, or 3. Are incapable of consenting to participation, or 4. Have any major obstetrical complications or fetal cardiac anomaly in the current or in a past pregnancy (as this changes the risk/benefit ratio discussion in regards to antidepressant use), or 5. Are unable to read or unable to speak or understand English and do not have someone that can read the PDA to them, or 6. Have a visual impairment that would prevent them from being able to view the website.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Women’s College Hospital
  • Collaborator
    • Ontario Ministry of Health and Long Term Care
  • Provider of Information About this Clinical Study
    • Principal Investigator: Simone Vigod, Psychiatrist – Women’s College Hospital
  • Overall Official(s)
    • Simone Vigod, MD, MSc, Principal Investigator, Women’s College Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.